Clinical, genetic, and nutritional determinants of INR: role of plasma warfarin and hydroxylated metabolite levels in anticoagulated Mexican patients
- 3 November 2025
- journal article
- research article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (3) , 786-799
Abstract
Warfarin dosing guided by INR fails to account for pharmacokinetic/pharmacodynamic variability, leading to suboptimal outcomes; genetic and clinical factors, such as VKORC1 polymorphism and comorbidities, could refine dosing strategies and improve anticoagulation safety. The aim of this was to identify the main determinants of INR variability in Mexican patients under long-term anticoagulation therapy. For this purpose, patients undergoing warfarin treatment were included and a clinical data was retrieved from medical record. A bioanalytical HPLC method to quantify warfarin (CPW) and its primary metabolite, 7-OH warfarin (CP7OH), in plasma samples was standardized and validated. INR variability was assessed in relation to Charlson comorbidity index (CCI), warfarin dose, drug interactions, vitamin K intake, CPW, CP7OH, metabolic ratio, and VKORC1 1693 polymorphism using univariate and multivariate analysis. The results showed that among 22 patients (64% women) with atrial fibrillation and aortic-mitral valve replacement, warfarin dosing ranged from 8.75 to 55 mg/week (median: 22.5 mg/week). Over half (68.2%) did not achieve the therapeutic INR goal (2.0–3.5). VKORC1 1693 genotype frequencies were GG (36%), GA (50%), and AA (14%), with AA carriers requiring lower maintenance doses (p<0.01). Multivariate analysis incorporating CCI, CPW and CP7OH explained up to 70% of INR variability (p<0.01). Furthermore, currently reported dosing algorithms showed limited accuracy in predicting the appropriate warfarin dose in this cohort. Overall, INR variability depends on plasma warfarin levels, metabolite concentration, and key comorbidities. Therefore, tailored population models are essential to optimize anticoagulation therapy in Mexico. This research highlights the need for more inclusive studies incorporating genetic and clinical factors to refine warfarin dosing and improve outcomes. Graphical abstract Created in BioRender. Rodriguez, O. (2025) https://BioRender.com/t2ww5to.Keywords
This publication has 52 references indexed in Scilit:
- Outcomes of Warfarin Home INR Monitoring vs Office-Based Monitoring: a Retrospective Claims-Based AnalysisJournal of General Internal Medicine, 2023
- Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative reviewInternational Journal of Clinical Pharmacy, 2022
- Risk of major bleeding and thromboembolism in Asian patients with nonvalvular atrial fibrillation using direct oral anticoagulants versus warfarinInternational Journal of Clinical Pharmacy, 2021
- Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trialNaunyn-Schmiedeberg's Archives of Pharmacology, 2021
- Genotype frequencies of VKORC1 and CYP2C9 in Native and Mestizo populations from Mexico, potential impact for coumarin dosingGene, 2015
- Allele frequency distribution of CYP2C9*2 and CYP2C9*3 polymorphisms in six Mexican populationsGene, 2013
- Pharmacogenomics of Warfarin dose requirements in HispanicsBlood Cells, Molecules, and Diseases, 2011
- Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinicJournal of Thrombosis and Thrombolysis, 2010
- Population pharmacokinetics of racemic warfarin in adult patientsJournal of Pharmacokinetics and Biopharmaceutics, 1985
- Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in manClinical Pharmacology & Therapeutics, 1974